The global cold plasma market size is expected to reach USD 495.9 million by 2033, registering a CAGR of 14.6% from 2026 to 2033, according to a new report by Grand View Research, Inc. Increasing use of cold plasma in medical treatment and rising cases of Hospital-Acquired Infections (HAI) are the key driving factors for the global market. In healthcare industry, plasma technology has been in use for some time and it continues to help improve various treatments. One of the major properties of cold plasma is the ability to kill bacteria and prevent infection. Therefore, it acts as an effective healing solution. It also accelerates healing process and prevent patient from discomfort.

Cold plasma is used in the treatment of chronic wounds and burns. The bacterial cells, including Multidrug Resistant (MDR) bacteria, are instantly killed after being exposed to cold plasma. As per an article published by the Medical Xpress, Med Tech Europe, around 4.0 million people in Europe suffer from non-healing wounds every year. It also reported that a burn patient in Germany was treated using prototype plasma treatment. Moreover, as per a research published by The National Center for Biotechnology Information (NCBI), a patient suffering with two second-degree burns was treated with cold plasma, which healed the itching and pain and presented new tissue after the second treatment. Such cases are anticipated to promote the usage of cold plasma in various wound treatments.

This growth is attributed to the overall development of the healthcare industry, which has increased the demand for advanced technologies to enhance patient treatment procedures and make them safe and non-invasive.

In addition, cold plasma technology enhances applications such as cancer treatment, sterilization, and wound healing, driving the market's growth significantly. Cold plasma, also known as non-equilibrium plasma, is a partially ionized gas in which the temperatures of its constituents differ significantly. It is generated by supplying energy to gases, creating reactive species useful in various applications, including medical treatments, sterilization, and food safety, without the harmful effects of high-temperature plasmas.

Request sample report of Cold Plasma Market@ https://www.grandviewresearch.com/industry-analysis/cold-plasma-market/request/rs1

According to research by the University of Michigan, cold plasma is the most effective solution for removing dangerous airborne viruses. Non-thermal plasma can remove up to 99% of the virus in fractions of a second. This creates opportunities for doctors to treat patients with breathing problems using cold plasma technologies.

Increasing applications across various industries, including textiles, food safety, and medical sectors, significantly contribute to market growth. In addition, the rising demand for sustainable and efficient processing technologies, alongside innovations in food decontamination and medical treatments, further fuels this growth. Furthermore, the market is supported by advancements in atmospheric cold plasma technology, which offers eco-friendly solutions without harmful chemicals, enhancing its attractiveness to diverse industries.

The rising incidence of hospital-acquired infections (HAIs) is a critical driver of the cold plasma market, as healthcare facilities seek effective solutions for infection control and sterilization. For instance, according to the World Health Organization (WHO), HAIs affect hundreds of millions of patients worldwide each year, leading to increased morbidity, extended hospital stays, and higher healthcare costs. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that about 1 in 31 hospital patients has at least one HAI on any given day, contributing to approximately 99,000 deaths annually.

Rising cases of hospital-acquired infections (HAIs) are significantly driving the growth of the cold plasma market. Cold plasma technology is increasingly recognized for its effective antimicrobial properties, making it a valuable solution for infection control and sterilization in healthcare settings. As hospitals strive to reduce HAIs and enhance patient safety, the demand for innovative technologies like cold plasma continues to rise. For instance, according to the Global Report on Infection Prevention and Control (2024) by the World Health Organization (WHO), out of every 100 patients in acute-care hospitals, 7 patients in high-income countries (HICs) and 15 patients in low-income countries (LMICs) acquired at least one HAI during their hospital stay.